APA
Bentz J., O'Connor M. P., Bednarczyk D., Coleman J., Lee C., Palm J., Pak Y. A., Perloff E. S., Reyner E., Balimane P., Brännström M., Chu X., Funk C., Guo A., Hanna I., Herédi-Szabó K., Hillgren K., Li L., Hollnack-Pusch E., Jamei M., Lin X., Mason A. K., Neuhoff S., Patel A., Podila L., Plise E., Rajaraman G., Salphati L., Sands E., Taub M. E., Taur J., Weitz D., Wortelboer H. M., Xia C. Q., Xiao G., Yabut J., Yamagata T., Zhang L. & Ellens H. (20131126). Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. : Drug metabolism and disposition: the biological fate of chemicals.
Chicago
Bentz Joe, O'Connor Michael P, Bednarczyk Dallas, Coleman Joann, Lee Caroline, Palm Johan, Pak Y Anne, Perloff Elke S, Reyner Eric, Balimane Praveen, Brännström Marie, Chu Xiaoyan, Funk Christoph, Guo Ailan, Hanna Imad, Herédi-Szabó Krisztina, Hillgren Kate, Li Libin, Hollnack-Pusch Evelyn, Jamei Masoud, Lin Xuena, Mason Andrew K, Neuhoff Sibylle, Patel Aarti, Podila Lalitha, Plise Emile, Rajaraman Ganesh, Salphati Laurent, Sands Eric, Taub Mitchell E, Taur Jan-Shiang, Weitz Dietmar, Wortelboer Heleen M, Xia Cindy Q, Xiao Guangqing, Yabut Jocelyn, Yamagata Tetsuo, Zhang Lei and Ellens Harma. 20131126. Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. : Drug metabolism and disposition: the biological fate of chemicals.
Harvard
Bentz J., O'Connor M. P., Bednarczyk D., Coleman J., Lee C., Palm J., Pak Y. A., Perloff E. S., Reyner E., Balimane P., Brännström M., Chu X., Funk C., Guo A., Hanna I., Herédi-Szabó K., Hillgren K., Li L., Hollnack-Pusch E., Jamei M., Lin X., Mason A. K., Neuhoff S., Patel A., Podila L., Plise E., Rajaraman G., Salphati L., Sands E., Taub M. E., Taur J., Weitz D., Wortelboer H. M., Xia C. Q., Xiao G., Yabut J., Yamagata T., Zhang L. and Ellens H. (20131126). Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. : Drug metabolism and disposition: the biological fate of chemicals.
MLA
Bentz Joe, O'Connor Michael P, Bednarczyk Dallas, Coleman Joann, Lee Caroline, Palm Johan, Pak Y Anne, Perloff Elke S, Reyner Eric, Balimane Praveen, Brännström Marie, Chu Xiaoyan, Funk Christoph, Guo Ailan, Hanna Imad, Herédi-Szabó Krisztina, Hillgren Kate, Li Libin, Hollnack-Pusch Evelyn, Jamei Masoud, Lin Xuena, Mason Andrew K, Neuhoff Sibylle, Patel Aarti, Podila Lalitha, Plise Emile, Rajaraman Ganesh, Salphati Laurent, Sands Eric, Taub Mitchell E, Taur Jan-Shiang, Weitz Dietmar, Wortelboer Heleen M, Xia Cindy Q, Xiao Guangqing, Yabut Jocelyn, Yamagata Tetsuo, Zhang Lei and Ellens Harma. Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. : Drug metabolism and disposition: the biological fate of chemicals. 20131126.